These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27994516)

  • 1. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 2. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
    Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
    Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
    Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
    Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
    Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data.
    Andersen KØ; Detlefsen S; Brusgaard K; Christesen HT
    Front Endocrinol (Lausanne); 2024; 15():1351624. PubMed ID: 38868744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
    Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
    J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of Pancreatic Neuroendocrine Tumors.
    Mohindroo C; McAllister F; De Jesus-Acosta A
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.
    Capurso G; Archibugi L; Delle Fave G
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):594-601. PubMed ID: 25619712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy.
    Gujarathi R; Abou Azar S; Tobias J; Polite BN; Setia N; Feinberg N; Appelbaum DE; Keutgen XM; Liao CY
    Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39093924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
    Geis C; Fendrich V; Rexin P; Di Fazio P; Bartsch DK; Ocker M; Quint K; Heverhagen AE
    J Surg Res; 2015 Apr; 194(2):388-393. PubMed ID: 25439321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times.
    Roy S; LaFramboise WA; Liu TC; Cao D; Luvison A; Miller C; Lyons MA; O'Sullivan RJ; Zureikat AH; Hogg ME; Tsung A; Lee KK; Bahary N; Brand RE; Chennat JS; Fasanella KE; McGrath K; Nikiforova MN; Papachristou GI; Slivka A; Zeh HJ; Singhi AD
    Gastroenterology; 2018 Jun; 154(8):2060-2063.e8. PubMed ID: 29486199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
    Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
    J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetics of neuroendocrine tumors.
    Öberg K
    Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors.
    Sato S; Tsuchikawa T; Nakamura T; Sato N; Tamoto E; Okamura K; Shichinohe T; Hirano S
    Oncol Rep; 2014 Dec; 32(6):2753-9. PubMed ID: 25310565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1.
    Marini F; Giusti F; Tonelli F; Brandi ML
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
    Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
    Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors.
    Ye Z; Chen H; Ji S; Hu Y; Lou X; Zhang W; Jing D; Fan G; Zhang Y; Chen X; Zhuo Q; Chen J; Xu X; Yu X; Xu J; Qin Y; Gao H
    Acta Biochim Biophys Sin (Shanghai); 2022 Nov; 54(11):1599-1609. PubMed ID: 36604142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
    Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
    Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.